AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
157.12
+0.22 (+0.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.90
Open156.81
Bid150.00 x 200
Ask176.00 x 300
Day's Range154.90 - 157.22
52 Week Range142.81 - 256.80
Volume1,700,610
Avg. Volume3,307,780
Market Cap51.47B
Beta1.23
PE Ratio (TTM)N/A
EPS (TTM)-13.20
Earnings DateApr 30, 2018
Forward Dividend & Yield2.88 (1.73%)
Ex-Dividend Date2018-02-27
1y Target Est210.35
Trade prices are not sourced from all markets
  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist21 hours ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • ACCESSWIRE22 hours ago

    Today's Research Reports on Trending Tickers: Allergan and Incyte Corporation

    NEW YORK, NY / ACCESSWIRE / April 25, 2018 / The markets recent slide continued Tuesday as concerns of rising interest rates continued to plague investors. On Tuesday, the yield on the benchmark on the ...

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist23 hours ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Reutersyesterday

    Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc (OIS.N), a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • Reuters2 days ago

    U.S. Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc, a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
    Zacks2 days ago

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

    While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

  • Rival Botox Maker Says Patients Can't Wait for It to Hit
    Bloomberg3 days ago

    Rival Botox Maker Says Patients Can't Wait for It to Hit

    Patients are already clamoring for “the longer acting Botox,” a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News in an interview Friday. The launch won’t happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer acting product for therapeutic goals. "People underestimate the power of this data,” Browne said, he’s expecting it to be a “major de-risking event” for Revance when results from the study, known as “Sakura” read out later this year.

  • The Wall Street Journal5 days ago

    [$$] Takeda Increases Takeover Proposal for Drug Rival Shire

    Japan’s Takeda said it had made a sweetened proposal to buy Shire after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected.

  • Moody's6 days ago

    Allergan Finance, LLC -- Moody's: Allergan's strategic review increases event risk

    Moody's Investors Service commented that Allergan's ongoing strategic review of potential actions that would create shareholder value raises event risk that financial leverage could increase. There is no impact on the Baa3 ratings on rated subsidiaries including Allergan, Inc. and Allergan Funding SCS, or on the stable rating outlook. For additional information please see Moody's Issuer Comment on Allergan plc available on www.moodys.com.

  • Investopedia6 days ago

    Allergan Declines to Bid on Shire

    Botox maker Allergan said it will no longer consider bidding for Shire.

  • Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
    Zacks6 days ago

    Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

    Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

  • ACCESSWIRE6 days ago

    Today’s Research Reports on Trending Tickers: TransEnterix and Allergan

    NEW YORK, NY / ACCESSWIRE / April 20, 2018 / U.S. markets slipped Thursday as tech and consumer staples sectors disappointed investors. The Dow Jones Industrial Average declined 0.34 percent to close at ...

  • PR Newswire6 days ago

    Allergan Showcases Leadership in Neurosciences with 25 Presentations at the American Academy of Neurology Annual Meeting in Los Angeles

    -- Phase 3 Oral CGRP Results for Ubrogepant Accepted as Late Breaker Emerging Science Presentation -- DUBLIN , April 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company ...

  • Financial Times6 days ago

    [$$] Shire shares down 3.7% after Allergan rules out bid

    Allergan had made it known that it had contemplated an offer but then decided against it, which sent Shire’s share price down at 3,823 pence from yesterday’s close at 3,831 pence. Takeda shares fell by 4.67 per cent. Shire on Friday confirmed that Allergan had backed away.

  • The Wall Street Journal6 days ago

    [$$] Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy

    Drugmaker Shire rebuffed a takeover bid from rival Takeda Pharmaceutical, then Allergan took a look.

  • Allergan Will Not Make Offer for Shire
    Bloomberg6 days ago

    Allergan Will Not Make Offer for Shire

    In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire. Bloomberg's Lisa Du reports on "Bloomberg Daybreak: Asia." ...

  • Shire to World: Let the Bidding Begin
    Motley Fool6 days ago

    Shire to World: Let the Bidding Begin

    Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.

  • Financial Times6 days ago

    [$$] Best of Lex: your weekly round-up

    Dear readers, This week the Financial Times described the world’s smallest-ever chemistry experiment : the creation of a molecule from two single atoms. What made this achievement even more remarkable ...

  • Reuters6 days ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Reuters6 days ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed
    Investor's Business Daily7 days ago

    Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed

    In a rapid turnaround, Allergan said late Thursday it doesn't intend to bid on Shire — leaving thrice-rebuffed Takeda Pharmaceuticals alone in the race for the rare disease drugmaker.

  • Why Is Allergan (AGN) Stock Falling Today?
    Zacks7 days ago

    Why Is Allergan (AGN) Stock Falling Today?

    Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.

  • Allergan Does Not Intend to Make Offer for Shire
    Bloomberg7 days ago

    Allergan Does Not Intend to Make Offer for Shire

    Bloomberg's Drew Armstrong discusses the latest on Allergan, which says they not intend to make an offer for Shire. He speaks with Lisa Abramowicz and Julia Chatterley on "Bloomberg Markets." ...

  • Japan's Takeda takeover bid causes investor headache
    Reuters Videos6 days ago

    Japan's Takeda takeover bid causes investor headache

    Takeda Pharmaceutical shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make after London-listed drugmaker Shire rejected its latest $63 bln bid. As Kate King reports, Botox-maker Allergan has also pulled out of the bidding battle.

  • Allergan Will Not Make Offer for Shire
    Bloomberg Video6 days ago

    Allergan Will Not Make Offer for Shire

    Apr.19 -- In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire. Bloomberg's Lisa Du reports on "Bloomberg Daybreak: Asia."